Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma
暂无分享,去创建一个
M. Imamura | H. Aikata | E. Murakami | T. Kawaoka | H. Fujino | T. Nakahara | W. Okamoto | M. Yamauchi | Yuwa Ando | Kensuke Naruto | Yumi Kosaka | Kenichiro Kodama | Ryoichi Miura | Shigeki Yano | Masanari Kosaka | Yusuke Johira | Yuki Shirane | Serami Murakami | K. Amioka | S. Uchikawa | Atsushi Ohno
[1] M. Imamura,et al. Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab , 2021, Medicine.
[2] M. Kudo,et al. Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD−1/PD-L1 Checkpoint Blockade , 2020, Cancers.
[3] M. Kudo. A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE , 2019, Liver Cancer.
[4] M. Kudo. Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials , 2019, Liver Cancer.